SpringWorks Therapeutics (SWTX) announced that the U.S. FDA has approved Gomekli, SpringWorks’ MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. With the approval, SpringWorks was granted a rare pediatric disease priority review voucher by the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- FDA approves SpringWorks’ mirdametinib for adult and pediatric NF1 patients
- SpringWorks Therapeutics price target raised to $65 from $55 at BofA
- Buy Rating on Springworks Therapeutics Driven by Potential Merck Acquisition and Strong Drug Market Potential
- Merck KGaA confirms ‘advanced’ talks to acquire SpringWorks
- SpringWorks shares up 39% to $55.90 after Merck KGaA confirms talks